Research programme: smallpox vaccines - Tonix Pharmaceuticals/University of Alberta

Drug Profile

Research programme: smallpox vaccines - Tonix Pharmaceuticals/University of Alberta

Alternative Names: TNX 801

Latest Information Update: 21 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Leder Laboratories; University of Alberta
  • Developer Tonix Pharmaceuticals Holding Corp
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Smallpox

Most Recent Events

  • 02 Mar 2017 Preclinical trials in Smallpox (Prevention) in Canada
  • 02 Mar 2017 Preclinical trials in Smallpox (Prevention) in USA
  • 02 Mar 2017 University of Alberta and Tonic Pharmaceuticals agree develop TNX 801 in Small pox (Prevention)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top